Eli Lilly Agrees to Acquire Calytrix for Up to $1.5 Billion Before Human Clinical Trials

Eli Lilly agreed to acquire privately held Calytrix Bio for up to $1.5 billion in cash, including an undisclosed upfront payment and additional clinical and regulatory milestones. Calytrix is developing a preclinical antibody targeting mutated calreticulin (CALR), a disease-associated driver in certain myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis. The experimental treatment is intended to target disease-driving cells while sparing healthy blood-forming cells, but has not yet entered human trials. The acquisition follows Lilly's earlier purchase of Ajax Therapeutics and expands its hematology strategy beyond its established metabolic portfolio.

Reuters

Reuters · November 16, 2026

Why it matters strategically

Lilly is acquiring a mechanism and development opportunity before human proof of concept.

The headline transaction value therefore needs to be distinguished from the upfront consideration and the probability-weighted value of contingent payments.

Previous
Previous

Biogen's Anti-Tau Therapy Shows Increasing Clinical Benefit at Two Years

Next
Next

FDA Approves Roche's Giredestrant: The Next Competitive Test in ESR1-Mutated Breast Cancer